Evidence map›Paper›PMID 31483549›Full record

ArticleAddiction (Abingdon, England)2019

Cost-effectiveness of population-level proactive tobacco cessation outreach among socio-economically disadvantaged smokers: evaluation of a randomized control trial.

Viengneesee Thao, John A Nyman, David B Nelson, Anne M Joseph, Barbara Clothier, Patrick J Hammett, Steven S Fu

Abstract readEvaluation Study
In one paragraph

Article in Addiction (Abingdon, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Proactive tobacco treatment for veterans with posttraumatic stress disorder.Psychological trauma : theory, research, practice and policy · 2021
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Receipt of Cessation Treatments Among Medicaid Enrollees Trying to Quit Smoking.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2021
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Viengneesee ThaoUniversity of Minnesota School of Public Health, Minneapolis, MN, USA.
John A NymanUniversity of Minnesota School of Public Health, Minneapolis, MN, USA.
David B NelsonVA Health Services Research and Development Center for Care Delivery and Outcomes Research (CCDOR), Minneapolis, MN, USA.
Anne M JosephDepartment of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA.
Barbara ClothierVA Health Services Research and Development Center for Care Delivery and Outcomes Research (CCDOR), Minneapolis, MN, USA.
Patrick J HammettUniversity of Minnesota School of Public Health, Minneapolis, MN, USA.
Steven S FuVA Health Services Research and Development Center for Care Delivery and Outcomes Research (CCDOR), Minneapolis, MN, USA.ORCID 0000-0002-2246-9825

Funding

Effectiveness of Proactive Tobacco Treatment in Diverse Low Income SmokersR01CA141527 · NCI · UNIVERSITY OF MINNESOTA · PI FU, STEVEN, JOSEPH, ANNE · 2009 to 2014
$2.4M
NCI NIH HHS R01 CA141527
6 · The paper itself

Abstract

aimsTo estimate the cost-effectiveness at population-level of the OPT-IN proactive tobacco cessation outreach program for adult smokers enrolled in publicly funded health insurance plans for low-income persons (e.g. Medicaid).

designCost-effectiveness analysis using a state transition model based on data from the Offering Proactive Treatment Intervention (OPT-IN) randomized control trial.

settingThe trial was conducted in Minnesota, USA, and the economic analysis was conducted from the Medicaid program perspective.

participantsData were used from 2406 smokers who were randomized into the intervention or comparator groups. INTERVENTION AND COMPARATOR: The intervention was comprised of proactive outreach (mailed invitation and telephone calls) and free cessation treatment (nicotine replacement therapy and intensive telephone counseling). The comparator was usual care, which comprised access to a primary care physician, insurance coverage of Food and Drug Administration (FDA)-approved smoking cessation medications and the state's telephone quitline. MEASUREMENTS: Smoking status, quality of life and health-care use at varying times, including at baseline and 1 year.

findingsThe OPT-IN program cost an average of $84 per participant greater than the comparator. One year after randomization, the population-level, 6-month prolonged smoking abstinence rate was 16.5% in the proactive outreach intervention group and 12.1% in the usual care group (P < 0.05). The model projected that the proactive outreach intervention added $78 in life-time cost and generated 0.005 additional quality-adjusted life-years (QALYs), with an expected incremental cost-effectiveness ratio of $4231 per QALY. Probabilistic sensitivity analysis found that the proactive outreach intervention would be cost-effective against a willingness-to-pay threshold of $50 000/QALY approximately 68% of the time.

conclusionsPopulation-level proactive tobacco treatment with personal telephone outreach was effective in achieving higher population-level quit rates and was cost-effective at various willingness-to-pay thresholds, compared with usual care (i.e. reactive treatment). Taken together with prior research, population-level proactive tobacco cessation outreach programs are judged to be highly cost-effective over the long term.

Indexed as

Cost-Benefit AnalysisAdultFemaleHumansMaleMedicaidMiddle AgedPovertyQuality of LifeRandomized Controlled Trials as TopicSmoking CessationTobacco Use CessationUnited StatesVulnerable PopulationsCost-effectivenesshealth-care disparitieslow-income populationMarkov modelproactive outreachsmoking cessation

Identifiers

PMID31483549
PMCPMC6899559

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.